Equities Analysts Issue Forecasts for Genelux Q3 Earnings

Genelux Corporation (NASDAQ:GNLX) – Research analysts at HC Wainwright dropped their Q3 2026 earnings per share (EPS) estimates for Genelux in a report issued on Friday, August 14th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings of ($0.21) per share for the quarter, down from their prior forecast of ($0.20). The consensus estimate for Genelux’s current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for Genelux’s Q4 2026 earnings at ($0.19) EPS, FY2027 earnings at ($0.77) EPS, FY2028 earnings at $0.61 EPS, FY2029 earnings at $1.63 EPS and FY2030 earnings at $2.52 EPS.

Genelux (NASDAQ:GNLX) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01).

GNLX has been the subject of a number of other reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Genelux in a research note on Friday, July 17th. Wall Street Zen lowered Genelux from a “sell” rating to a “strong sell” rating in a report on Saturday. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $18.00.

Genelux Price Performance

Shares of NASDAQ:GNLX opened at $2.70 on Tuesday. The stock has a market cap of $121.07 million, a price-to-earnings ratio of -3.14 and a beta of 0.60. Genelux has a 12 month low of $2.29 and a 12 month high of $8.53. The stock’s 50 day moving average price is $2.89 and its 200 day moving average price is $2.77.

Insiders Place Their Bets

In related news, Director John Thomas sold 10,000 shares of Genelux stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $2.98, for a total value of $29,800.00. Following the transaction, the director owned 472,784 shares of the company’s stock, valued at approximately $1,408,896.32. This trade represents a 2.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director John W. Smither sold 12,000 shares of the business’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $2.91, for a total value of $34,920.00. Following the sale, the director owned 91,403 shares in the company, valued at approximately $265,982.73. The trade was a 11.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 25,868 shares of company stock valued at $76,120 in the last quarter. 7.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Genelux

A number of large investors have recently made changes to their positions in GNLX. Jefferies Financial Group Inc. purchased a new stake in shares of Genelux in the 4th quarter valued at approximately $48,000. GSA Capital Partners LLP purchased a new position in Genelux during the 2nd quarter valued at about $35,000. Squarepoint Ops LLC acquired a new position in shares of Genelux in the 4th quarter valued at about $52,000. Balyasny Asset Management L.P. acquired a new position in shares of Genelux in the 4th quarter valued at about $94,000. Finally, Align Financial LLC purchased a new stake in shares of Genelux in the fourth quarter worth approximately $123,000. Institutional investors and hedge funds own 37.33% of the company’s stock.

About Genelux

Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company’s programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux’s lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.

Genelux’s pipeline leverages its experience with the GL-ONC1 construct to explore combination strategies with chemotherapy and immuno-oncology agents.